Search
Oncology Institute Inc
TOIAdd to Watchlist
5.280USD
-0.230-4.17%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
522.00MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Oncology Institute Inc is 8.50, ranking 15 out of 75 in the Healthcare Providers & Services industry. The average price target is 6.50, with a high of 8.00 and a low of 5.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
7.750
Target Price
+46.78%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
68
Total
8
Median
8
Average
Company name
Ratings
Analysts
Oncology Institute Inc
TOI
4
CVS Health Corp
CVS
29
HCA Healthcare Inc
HCA
26
Teladoc Health Inc
TDOC
26
Natera Inc
NTRA
24
Tenet Healthcare Corp
THC
23
1
2
3
...
14
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Oncology Institute Inc's expected revenue for the next quarter?
Oncology Institute Inc's expected revenue is 157.09M.
What is Oncology Institute Inc's price target?
Analysts forecast that Oncology Institute Inc's price target is USD 6.50, with the highest forecast at USD 8.00 and the lowest forecast at USD 5.00.
How have Oncology Institute IncTOI's recent earnings per share performed?
The market expectation was USD -0.02, while Oncology Institute IncTOI's earnings per share (EPS) for the previous quarter was USD -0.06. EPS for the next quarter is expected at USD -0.07.
What is the analyst rating for Oncology Institute Inc?
Based on the ratings of Oncology Institute Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.